Zihua Embrocation

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains of muscles and joints associated with conditions such as simple backache, arthritis, strains, bruises, and sprains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children 12 years of age and older are instructed to apply the medication to the affected area no more than 3 to 4 times daily. The application should be performed liberally, with gentle rubbing into the affected area to ensure proper absorption.

For children under 12 years of age, it is essential to consult a healthcare professional prior to use. The medication should not be used in any manner other than as directed.

Contraindications

Use of this product is contraindicated in the following situations:

Application to wound or damaged skin is prohibited due to the potential for adverse effects. Additionally, tight bandaging is not recommended, as it may compromise circulation and lead to further complications.

Warnings and Precautions

For external use only, this product should be applied with caution to avoid contact with the eyes and mucous membranes. In the event of excessive skin irritation, the use of the product must be discontinued immediately.

It is imperative to avoid application on wound or damaged skin, and tight bandaging should be avoided to ensure proper skin health and product efficacy.

Healthcare professionals should advise patients to stop using the product and seek medical attention if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms improve and then recur within a few days, pain continues for more than 10 days, or if redness is observed. Special attention should be given to conditions affecting children under 12 years of age, as they may require different management.

In cases of accidental ingestion, it is crucial to seek emergency medical assistance or contact a poison control center immediately.

Side Effects

Patients using this product should be aware that it is intended for external use only. Care should be taken to avoid contact with the eyes or mucous membranes. In the event of excessive skin irritation, discontinuation of use is advised.

Participants are instructed to stop use and consult a healthcare professional if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms clear up and then recur within a few days, pain persists for more than 10 days, or if redness is present. Additionally, special caution is warranted for conditions affecting children under 12 years of age, and medical advice should be sought in such cases.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Zihua Embrocation (camphor menthol methyl salicylate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional prior to use, as specific conditions may affect this population. It is essential to evaluate the appropriateness of treatment in children, considering their unique physiological and developmental needs.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients may use this medication as no specific safety concerns regarding pregnancy have been noted. There are no dosage modifications required for pregnant individuals, and no special precautions regarding the use of this medication during pregnancy are included in the prescribing information. Healthcare professionals should continue to monitor the health of pregnant patients and their fetal outcomes as part of standard care.

Lactation

There is no specific information regarding the use of this drug in lactating mothers or any lactation considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to nursing mothers, as the effects on breastfed infants are not established. It is advisable to monitor breastfed infants for any potential adverse effects if the mother is treated with this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient’s condition is critical. Recommended actions include:

1. Assessment and Monitoring: Conduct a thorough evaluation of the patient’s vital signs, level of consciousness, and any observable symptoms. Continuous monitoring may be necessary to detect any changes in the patient’s status.

2. Supportive Care: Initiate supportive measures as required, which may include airway management, oxygen supplementation, intravenous fluids, and other interventions to stabilize the patient.

3. Toxicology Consultation: Consider consulting a poison control center or a toxicologist for guidance on specific management strategies tailored to the substance involved in the overdose.

4. Decontamination: If appropriate and within a reasonable timeframe, decontamination procedures such as activated charcoal administration may be considered, provided the patient is alert and able to protect their airway.

5. Symptomatic Treatment: Address any specific symptoms that arise during the management of the overdose, ensuring that the treatment is aligned with the clinical presentation.

It is imperative for healthcare professionals to document all findings and interventions thoroughly and to communicate effectively with the patient’s care team throughout the management process.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children to prevent accidental poisoning. In the event of ingestion, patients should seek medical assistance or contact a poison control center immediately.

Patients should be instructed to discontinue use and consult a doctor if their condition worsens, if symptoms persist for more than 7 days, or if symptoms resolve and then recur within a few days. Additionally, they should seek medical advice if pain persists for more than 10 days, if there is any redness present, or if the product is intended for use in children under 12 years of age.

When using this product, patients must be cautioned against applying it to wounds or damaged skin. They should also be informed not to bandage the area tightly to avoid complications.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light to prevent degradation. After opening, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

Patients aged 12 years and older are advised to apply the medication to the affected area no more than 3 to 4 times daily. It is recommended to apply the product liberally and gently rub it into the affected area. No further information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Zihua Embrocation, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)